Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Finance and Investment

Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services

Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.

Axithra Strengthens its Board of Directors

The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy

Bridging the gap between academia and the sports tech industry

For scientists or budding entrepreneurs with the next big idea in sports tech, the road from conceptualization to product can seem perilous, with many pitfalls along the way. To stand a chance at getting your research out of the lab and into the hands of athletes, it’s essential to start off on the right foot. Read on to see how the collaboration of scientists and sports tech development experts is helping this unique ecosystem in Belgium to flourish.

Flanders as a knowledge hub in the current Benelux life sciences ecosystem

At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.

V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

Fraud in scientific institutes: a crack in the fabric of science

The pursuit of scientific knowledge is at the heart of human progress – it leads to ground-breaking discoveries that have transformed our understanding of the world and our place within it. However, this noble pursuit is not without its blemishes. Scientific fraud – the deliberate misrepresentation of data or results to deceive the scientific community – poses a serious threat to the integrity of the scientific enterprise in both academia and industry. So, what can we do about it?

Fund+ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk in potential 1-billion-euro deal

Novo Nordisk will acquire Cardior Pharmaceuticals for up to 1.025 billion euros, including upfront and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in RNA-based therapies that have the potential to prevent, repair and reverse diseases of the heart. The company’s approach targets distinctive non-coding RNAs to address the root causes of cardiac dysfunctions and achieve lasting patient impact.

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Azalea Vision Secures Prestigious European Innovation Council (EIC) Transition Grant

Innovative Smart Contact Lens Developer Awarded €2.5M in Funding for Groundbreaking Ocular Health Technology

V-Bio Ventures portfolio company Protealis secures EUR 22 million in oversubscribed B round funding to propel sustainable plant protein seed solutions

Protealis, a leading innovator in seed solutions for sustainable plant proteins based in Ghent, Belgium, proudly announced today the successful completion of its B-Round funding, raising a substantial EUR 22 million.

How the Chair of the Board can empower a first-time biotech CEO

Stepping into the role of a Chief Executive Officer (CEO) for the first time can be a daunting prospect. In the biotech industry, the journey is marked by a unique set of hurdles, from scientific complexities, to regulatory intricacies, finance, HR, and interactions with a wide range of stakeholders. In this dynamic landscape, the role of the Chair of the Board of Directors becomes pivotal. The Chair is well-positioned to empower and support first-time CEOs, but good synergy between the duo is paramount for success.

Managing the hype cycle of innovative medical device development

As a CDMO in the life science industry, Unitron has a focus on the development and manufacturing of “electronics-inside” medical devices and the associated regulatory trajectory. The journey from innovative ideas to successful products are often bumpy and filled with challenges. Having a good understanding of this process and managing it well will boost your chances of success.

V-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesity

VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a new spin-off company based on research at the VIB-UGent Center for Inflammation Research. With an initial seed financing round supported by V-Bio Ventures, Qbic and VIB, the spin-off company is entering the obesity space with an entirely novel therapeutic approach.

Obulytix is developing a revolutionary solution for antibiotic resistance

Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.

The rise of women’s health

It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a rush of ‘pink’ fundraising for women’s health start-ups. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?